Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383384 | 0.88 | KDM4E (0.49) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL384772 | 0.86 | SCD (0.51) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL384774 | 0.86 | SCD (0.51) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL384773 | 0.86 | SCD (0.51) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL13813249 | 0.85 | CXCR3 (0.39) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL385660 | 0.85 | SGPL1 (0.39) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL13799809 | 0.84 | HCRTR2 (0.39) | KDM4ELMNAABL1SMN1; SMN2HPGD | |
| SCHEMBL383378 | 0.84 | HCRTR2 (0.39) | KDM4ELMNAABL1SMN1; SMN2HPGD | |
| SCHEMBL385013 | 0.84 | HCRTR1 (0.51) | KDM4ELMNAABL1HRH3SMN1; SMN2 | |
| SCHEMBL10107126 | 0.84 | HCRTR1 (0.51) | KDM4ELMNAABL1HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994094-B2 | N-pyridylpiperidine compound, method for producing the same, and pest control agent | OTSUKA AGRITECHNO CO., LTD. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100137582-A1 | N-PYRIDYLPIPERIDINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PEST CONTROL AGENT | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137582-A1 | N-PYRIDYLPIPERIDINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND PEST CONTROL AGENT | HRH4, NOX4, PRDX4 | KDM4E 471/4885LMNA 4100/4885ABL1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.